Latest News
-
WAYNE, Pa. — Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN™ docetaxel, a new QTORIN™ program...
-
PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its robust hematology portfolio through more than 90 company- and partner-sponsored disclosures, including 24 oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana, from...
-
RESEARCH TRIANGLE PARK, N.C. — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in its Phase 1/2 clinical trial evaluating...
